156334-89-3

Upstream product

• 156334-84-8 (R)-1--3-chloro-2-propanol 
• 156334-85-9 (R)-(-)-2-chloromethyl-4-(4-fluorobenzyl)morpholine 
• 156334-80-4 (R)-(+)-3-chloro-1-(4-fluorobenzylamino)-2-propanol 
• 140-75-0 para-fluorobenzylamine 
• 156925-20-1 (R)-(-)-<4-(4-fluorobenzyl)-2-morpholinyl>methyl p-toluenesulfonate 
• 156816-52-3 (+/-)-<4-(4-fluorobenzyl)-2-morpholinyl>methyl p-toluenesulfonate 
• 156925-17-6 (+/-)-2-(chloromethyl)-4-(4-fluorobenzyl)morpholine 
• 156925-21-2 (R)-4-(4-fluorobenzyl)-2-morpholinylmethanol 
• 156816-54-5 (+/-)-4-(4-fluorobenzyl)-2-morpholinylmethanol 
• 156816-53-4 1-Chloro-3-[(4-fluoro-benzyl)-(2-hydroxy-ethyl)-amino]-propan-2-ol 
• 156925-22-3 (2R)-2-hydroxymethylmorpholine 
• 135065-70-2 (2R)-2-[(benzyloxy)methyl]morpholine 
• 459-57-4 4-fluorobenzaldehyde 
• 22116-33-2 2-(4-fluoro-benzyl-amino)-ethanol 

Relevant academic research and scientific papers

N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR

The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.

ASYMMETRIC SYNTHESIS OF THE ENANTIOMERS OF 2-AMINOMETHYL-4-(4-FLUOROBENZYL)MORPHOLINE, AN INTERMEDIATE OF MOSAPRIDE, A GASTROPROKINETIC AGENT

An efficient asymmetric synthesis of the enantiomers of 2-aminomethyl-4-(4-fluorobenzyl)morpholine (3) which has served as an intermediate of mosapride (1), a potential gastroprokinetic agent, was achieved by the conversion of enantiomeric 3-chloro-1-(4-f

Synthesis and biological activities of the optical isomers of (±)-4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]me thyl]benzamide (Mosapride)

The enantiomers, (S)-(-)-1 and (R)-(+)-1, of (+)-4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]met hyl]benzamide (mosapride) [(+)-1], a new and selective gastroprokinetic agent, were prepared from optically active [4-(4-fluorobenzyl)-2-morpholinyl]methylamines (S)-(-)-4 and (R)-(+)-4, respectively. The requisite (S)-(-)-4 and (R)-(+)-4 were prepared by optical resolution of [4-(4-fluorobenzyl)-2-morpholinyl]methyl p-toluenesulfonate [(+)-5] using (-)- and (+)-N-(p-toluenesulfonyl)glutamic acids, followed by amination of the tosyloxy groupe of (R)-(-)-5 and (S)-(+)-5, respectively. The absolute configurations of (R)-(-)-5 and (S)-(+)-5 were determined on the basis of an asymmetric synthesis of (R)-(-)-5 from (S)-(+)-benzyl glycidyl ether [(S)-(+)-11]. Mosapride and its enantiomers, (S)-(-)-1 and (R)-(+)-1, were essentially equipotent in serotonin 5-HT4 receptor agonistic activity on the electrically evoked contractions in isolated guinea pig ileum.